Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLQ-101 in Premature Neonates at High Risk of Developing ROP
NCT07093255Phase 1Recruiting
- Sponsor
- FELIQS
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ubiquinol in retinopathy of prematurity (ROP) (3 arms), sponsored by FELIQS. Primary endpoint: Frequency of adverse events. Started Apr 2026; status: recruiting.
02
Drugs
ubiquinol
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT07093255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07093255.